We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 05, 2022

Validation of the 70-Gene Signature Test (MammaPrint) to Identify Patients With Breast Cancer Aged ≥70 Years With Ultralow Risk of Distant Recurrence

Journal of Geriatric Oncology


Additional Info

Journal of Geriatric Oncology
Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥ 70 years with ultralow risk of distant recurrence: A population-based cohort study
J Geriatr Oncol 2022 Jul 21;[EPub Ahead of Print], I Noordhoek, E Bastiaannet, NA de Glas, J Scheepens, LJ Esserman, J Wesseling, AN Scholten, CP Schröder, SG Elias, JR Kroep, JEA Portielje, M Kleijn, GJ Liefers

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading